Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

May 8, 2024

NASDAQ US Health Care Biotechnology earnings 71 min

Earnings Call Speaker Segments

Diane Weiser

executive
#1

Good afternoon, and thank you for being with us on today's call. Robert Blum, our President and Chief Executive Officer, is going to kick things off with a look at the quarter and what's happened recently. Fady Malik, EVP of R&D, will give updates on aficamten, with a focus on SEQUOIA HCM, FOREST- HCM, and the recent interactions we've had with the FDA. Stuart Kupfer, SVP and Chief Medical Officer, will share further updates on the ongoing clinical trials of aficamten, MAPLE -HCM, and ACACIA -HCM, and he'll also talk about how CK-586 is progressing along with our emerging pipeline. Andrew Callos, EVP and Chief Commercial Officer, will discuss commercial readiness activities for aficamten. Sung Lee, our new EVP and Chief Financial Officer, is here with us today, though he's just listening in alongside us since this is his first day at Cytokinetics. Robert Wong, VP and Chief Accounting Officer, will give a financial overview of the past quarter; and last, Robert Blum will go over our corporate development strategies before wrapping up the call by reviewing the key milestones we expect for the year. Please be aware that parts of the following discussion, including our answers to questions, contain statements relating to future events and performance rather than historical facts, and these constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements. Additional information concerning factors that could cause our actual results to differ materially from those in these forward-looking statements is contained in our SEC filings, including our current report regarding our first quarter 2024 financial results, filed on Form 8-K that was furnished to the SEC today. We undertake no obligation to update any forward-looking statements after this call. And now, I will turn the call over to Robert.

Robert I. Blum

executive
#2

Diane, thank you, and I appreciate everyone being with us on today's call. During Q1, we achieved significant advancement in carrying out our portfolio centered on muscle biology, with the extensive development initiative for aficamten serving as its foundation. Following encouraging top-line data from SEQUOIA-HCM, our critical phase III study of aficamten involving individuals suffering from obstructive hypertrophic cardiomyopathy, we are operating at maximum speed to get ready for an ambitious schedule of presentations and publications due to take place throughout the year; beyond that, we remain intently focused on regulatory filings during the latter half of the year, on continuing to run the current clinical trials program, on speeding up our commercial readiness efforts, and on broadening our pipeline further. Although the top-line findings from SEQUOIA-HCM that we disclosed last December gave a thorough high-level picture of aficamten's safety and efficacy, one of our key objectives is to share the SEQUOIA-HCM results more completely at a major medical conference. We recently revealed that this venue will be the European Society of Cardiology's Heart Failure 2024 Congress in Lisbon coming up next week, on Monday, May 13, where three late-breaking clinical trial presentations tied to SEQUOIA-HCM will be given by us. Besides the primary results, two additional late breakers we have contain data from further analyses of SEQUOIA-HCM, about which Fady will provide details. He will likewise describe the continuous flow of presentations and publications we expect to share concerning aficamten across 2024, since we think this will effectively flesh out its next-in-class profile. Throughout the first quarter, we additionally interacted in a meaningful way with FDA prior to our anticipated NDA filing for aficamten in Q3 of this year. Two meetings with FDA took place during February, one being an initial meeting to go over the SEQUOIA-HCM results and the other a pre-NDA meeting addressing particular subjects tied to our submission. We are happy with what the agency told us, and we anticipate further talks happening this quarter, which will tackle particular questions we are raising regarding possible REMS scenarios; we have also been getting ready for our anticipated MAA submission with EMA, expected in Q4 of this year. Furthermore, during 2024, numerous other work streams and activities moved into the next stage of execution, most notably commercial readiness efforts, which Andrew will discuss in greater depth. Though SEQUOIA-HCM stands as the leading edge of the Phase 3 development program for aficamten, we currently have two additional Phase 3 clinical trials underway assessing aficamten, each offering further chances to broaden the clinical evidence use case and ideally connect with more patients in need. Naturally, we are also carrying on with our continuing open-label extension study, FOREST-HCM, in order to gather longer-term data regarding aficamten's safety and efficacy. As Stuart is going to explain in more detail, the Phase 3 study called MAPLE-HCM — which tests aficamten alone against metoprolol alone — should finish enrolling patients during the third quarter. With cardiac myosin inhibitors now appearing, doctors are starting to raise a question, and this trial will give an answer grounded in evidence: which of these drugs should be given first?... For aficamten, MAPLE-HCM could represent a significant opening, since our hope is that it might support a major shift in how treatment is practiced, something that new guidelines might reflect. Stuart will additionally provide news about ACACIA-HCM, our phase 3 trial of aficamten in people who have non-obstructive HCM, and he will likewise cover a third late-stage trial named CEDAR-HCM, which has just opened for enrollment among a pediatric group of patients with oHCM; we take particular satisfaction in holding a solid financial footing as the first quarter closed, together with our R&D programs that keep maturing. As I will discuss at greater length afterward on this call, our view is that we occupy a favorable spot regarding the choices we have for bringing in capital from diverse sources, which will further power our science on behalf of patients and produce growing shareholder value. Finally, we were happy to share recently that our hunt for a new CFO had concluded, and as the 8-K we filed presumably showed you, it is my pleasure to welcome Sung Lee aboard. At the outset of that search, we set a number of essential qualifications for the right person, among them experience at both large and mid-sized biopharma firms, commercial finance work on a global scale, and a demonstrated history of innovative financing, of financing deals. All of those things and then some are what Sung offers, and having him with us could not make us happier. Before joining Cytokinetics, Sung held the CFO role at Vir Biotechnology as well as MorphoSys AG and Sangamo Therapeutics. Earlier in his career, he spent over 14 years building expertise at Gilead, where he took on a range of positions and gained leadership experience in tax, accounting, operations, and IR. Sung will speak on our Q2 earnings call, and anyone who has not yet been introduced to him will get an opportunity to do so soon, at our conferences and one-on-one meetings coming up. So, I will now hand the call to Fady, please.

Fady I. Malik

executive
#3

Appreciate that, Robert. The thing everyone's focused on right now is the late-breaking clinical trial sessions we'll be delivering next week at Heart Failure 2024 in Lisbon. Naturally, those sessions feature the primary findings from SEQUOIA-HCM, giving a full picture of the baseline characteristics, the primary and secondary endpoints, subgroup analyses, and chosen exploratory endpoints. Beyond that, there are two more late breakers covering other analyses of data from the trial. One digs into the dosing and safety experience seen in SEQUOIA-HCM, while the other takes a close look at how aficamten improved exercise capacity, drawing on a detailed review of the CPET data. What these sessions offer goes past what the top-line press release contained — they deliver an in-depth examination of this extremely rich data set and what it means for clinical practice. As Robert noted, next week's sessions are just the start of our effort to thoroughly unpack the SEQUOIA-HCM results and assemble a comprehensive picture of the differentiated profile that keeps taking shape for aficamten. Our plan is aggressive: it kicks off with HFA and unfolds across a 12-month span through a series of presentations and publications that will shed further light on aficamten's efficacy and safety. Expect presentations at the European Society of Cardiology, the Heart Failure Society of America, and the American Heart Association meeting, plus accompanying publications in leading medical journals. Those will include deeper dives into the echocardiographic data, the Kansas City Cardiomyopathy Questionnaire data, CMR data, cardiac remodeling, and biomarker data, along with an integrated analysis of efficacy. We're eager to share more as the year goes on. Turning to FOREST-HCM, last month at ACC we shared additional 48-week data from 46 patients with obstructive HCM and FOREST-HCM showing that aficamten treatment is tied to sustained improvements in resting and Valsalva left ventricular outflow tract gradient, NYHA functional class, NT-proBNP, and measures of cardiac structure and function. On top of that, instances of left ventricular ejection fraction were quite rare and weren't linked to treatment interruptions or heart failure events. These findings keep strengthening the case for the safety and efficacy of longer-term aficamten treatment in OHCM; with close to 300 patients now enrolled in FOREST-HCM, we're eager to report additional longer-term data down the road. Importantly, over the quarter we had plenty of chances to engage with KOLs and treating clinicians in the community about the results generated so far from the aficamten program. The feedback has been extremely positive, and we think that once presented and published, the complete results will confirm that enthusiasm. More specifically, our therapeutic medical science liaisons have interacted with over 500 healthcare professionals and finished profiling physician practices that have HCM treatment programs. Meanwhile, our managed healthcare medical science liaisons engaged integrated delivery networks, or IDNs, regarding the SEQUOIA-HCM results and wrapped up work to build our payer clinical value narrative. Regarding the regulatory side, as Robert said, we had 2 meetings with the FDA in the first quarter before submitting our NDA. In the second quarter, we intend to interact with the FDA again, this time through a Type B meeting that will center on possible risk mitigation. Although that subject was raised in both prior meetings, this upcoming session gives us a chance to go into greater detail about aficamten's safety and pharmaceutical characteristics, talk about how they might affect various risk management strategies, and learn how the FDA views these issues; in these conversations with the FDA, we hold the view that aficamten's benefit risk profile justifies a risk mitigation strategy that mirrors the safety profile shown in SEQUOIA-HCM and FOREST-HCM. All in all, we continue to be optimistic and think these talks will shape our proposal for a differentiated risk mitigation approach in our NDA. As we have said before, we are planning a rolling submission for the NDA, which will let the FDA start reviewing completed modules. We anticipate starting and finishing the submission in the third quarter. As you can surely understand, an NDA involves an enormous amount of effort, and our teams are working hard toward this highly significant milestone for the company. At the same time, we are getting our marketing application ready, which we expect to file with the EMA in the fourth quarter of this year, and we are working with our partner, Ji Xing, in China to help their plans for an NDA as well. During the quarter, we were happy to bring on a new head of regulatory for Europe, who will direct regulatory strategy and product registration in Europe and assist with launch readiness activities. Although SEQUOIA-HCM is the main focus right now, it is accompanied and backed by further clinical trials and a development program for aficamten that we think could broaden the usefulness of cardiac myosin inhibitors. I will pass it to Stuart to say more about these further clinical trials and to give an update on our earlier stage clinical development pipeline.

Stuart Kupfer

executive
#4

Thank you, Fady. I'd like to begin by discussing the two Phase 3 studies we currently have underway, MAPLE-HCM and ACACIA-HCM. Our belief is that each of these trials could extend aficamten's potential advantages to a broader group of patients suffering from obstructive and non-obstructive HCM, while also lifting aficamten's standing within treatment guidelines. MAPLE-HCM is assessing whether aficamten, given alone, might be superior to metoprolol, also given alone, in individuals who have obstructive HCM, and it remains on schedule to finish enrollment during the third quarter. More than 75% of the sites we have globally are now activated, and we anticipate that sites located in China and South America will be joining MAPLE-HCM before long. We project that by the close of the second quarter we will have reached roughly 50% of our target enrollment, with a substantial jump in enrollment anticipated during the third quarter. Data from SEQUOIA-HCM have created a powerful momentum behind enrollment across our active studies, MAPLE-HCM included, and we have seen considerable eagerness among sites to finish the trial and carry us over the finish line; we anticipate that MAPLE-HCM will report results in 2025, near the point at which we are hoping to bring aficamten to market commercially, and should the findings be positive, they will supply the evidence base needed to potentially place aficamten in guidelines as a first-line therapy for Obstructive HCM. ACACIA-HCM, our pivotal Phase 3 study of aficamten involving patients who have symptomatic Non-obstructive HCM, is likewise about to enter what we expect will be a swift period of site activation and enrollment. Throughout the second quarter, we are sitting down with numerous investigators and study staff members at their sites across the globe, and we recently conducted a successful investigator meeting in San Francisco. Because of favorable findings from Cohort 4 of REDWOOD-HCM, physicians are excited about what aficamten may offer in treating patients with non-obstructive HCM, and we look forward to carrying on with enrollment during this year, aiming to complete it in 2025. Now shifting to a different but important patient group, earlier today we revealed the launch of an additional aficamten clinical trial, named CEDAR-HCM — a randomized, double-blind, placebo-controlled study along with an open label extension that will assess efficacy, pharmacokinetics, and safety of aficamten among pediatric patients who have symptomatic obstructive HCM. Two cohorts will be enrolled in CEDAR-HCM. The first cohort will include approximately 40 adolescents between 12 and 17 years of age. A second, younger cohort consisting of as many as 10 children between 6 and 11 years of age will start enrolling once data from a minimum of 20 adolescent patients backs both safety and dose selection for the younger group. For the adolescent cohort, aficamten's treatment regimen will match the one used in adults. In other words, once-daily doses ranging from 5 to 20 milligrams, chosen for each individual according to echocardiographic parameters. Primary and secondary endpoints will be assessed following 12 weeks of double-blind treatment. The primary endpoint is the change in Valsalva left ventricular outflow tract gradient, while secondary endpoints comprise change in resting gradient, measures of pharmacokinetic profile, cardiac biomarkers, and symptoms. Following 12 weeks of double-blind treatment, every patient will move into an open-label extension. Pediatric HCM might not be common, but it carries a significant danger of heart failure along with severe arrhythmias. When HCM shows up in children and adolescents, the way it presents is generally similar to how it appears in adults, and it brings with it shortness of breath, fatigue, and poor exercise tolerance, all of which affect overall quality of life. Given what we saw in the SEQUOIA-HCM results among adults, we feel optimistic that aficamten could turn out to be a promising option for this important segment of the HCM population. In the second quarter, we will also kick off a phase I trial looking at the pharmacokinetics, safety, and tolerability of aficamten in healthy Japanese participants... in order to push our global clinical program forward in that geography. On top of that, in the first quarter we moved CK-586 ahead — another cardiac myosin inhibitor — being developed for the possible treatment of a subgroup of patients who have heart failure with preserved ejection fraction, or HFpEF. Earlier today, we released top-line data from the phase I study of CK-586, which demonstrated that CK-586 was safe and well-tolerated among healthy participants, with generally linear pharmacokinetics. These results support moving the program forward into a phase II clinical trial, which we anticipate starting in the fourth quarter of this year. We intend to share the phase I study data in greater detail at a medical congress during the second half of the year. Our view is that CK-586, whose mechanism of action differs from aficamten's, could further unlock the potential biology of myosin modulation for patients with high unmet need. Lastly, additional work went on over the past quarter on our earlier-stage programs, which we expect to mature from our labs into the clinic later this year and next, reaching beyond muscle contractility into muscle metabolism and energetics. These emerging programs form a key part of our long-term vision as we keep pioneering the field of muscle biology and pharmacology. To that end, we're glad to be sponsoring a dedicated muscle biology symposium here in South San Francisco next Friday called CLIMB: Contemporary Landscapes in Muscle Biology. This one-day event will convene scientists, researchers, and emerging professionals to share innovative research in the field of muscle biology. The purpose of this gathering is to foster collaboration, facilitate networking opportunities, and promote scientific interdisciplinary dialogue, with the ultimate goal of driving advancements in the understanding and treatment of muscle-related diseases and disorders. With that, I'll turn the call over to Andrew.

Andrew Callos

executive
#5

Thank you, Stuart. Once we reported the top-line data from SEQUOIA-HCM near the close of last year, during Q1 we moved into the design and build stages for our go-to-market plans; we put effort into sharpening our market development campaign, which is slated to kick off at HFSA later in the year, and started designing and building our full patient support services offering, along with our specialty distribution approach; we kept bolstering the commercial team by bringing on new people, among them a U.S. patient marketing lead and a head of Germany — which, should it gain approval, would be the first European nation where we intend to introduce aficamten. Throughout 2024, recruitment within our commercial group and in Europe is going to stay limited, with additional hiring anticipated during 2025 and 2026, tied to regulatory milestones in the U.S; and to EU and reimbursement levels country by country within the EU. On that point, we're glad to keep witnessing additional favorable health technology assessments for the CMI class over the past several quarters, among them ones from Germany, France, and the UK, which points to a possibly favorable outlook for aficamten's future reimbursement across key nations, assuming European approval. During the quarter, we kept developing aficamten's value proposition for a range of stakeholders, such as payers and HTAs, by producing data in the areas of health, economics, and outcomes research, or HEOR. In Q1, over recent weeks, members of our team published and presented 8 HEOR abstracts addressing subjects such as how ethnicity, sex, region, and payer healthcare coverage affect outcomes in HCM, medical therapy usage, post-septal myectomy, and the long-term cost of care for patients who have symptomatic obstructive HCM. What we found regarding patient outcomes and costs tied to obstructive HCM further highlights the clinical and economic unmet need within this expanding patient population. Going forward, once we present and publish the primary results from SEQUOIA-HCM next week, we will keep engaging with US payers. Our payer and medical account team started conversations with every major payer during 2023, and starting in Q3 of this year, we intend to begin pre-approval information exchange with every major payer so they can review the SEQUOIA-HCM results, ensuring payers grasp the clinical meaningfulness of those results, plus the cost and outcome burden of obstructive HCM. I'm happy with how far we've come on commercial readiness during 2024. As I've mentioned previously, the obstructive HCM market has a customer base that is highly concentrated, which is common in specialty cardiology. In contrast to biopharma companies that preceded us and failed to meet market expectations, we think our emphasis on specialty cardiology, anchored by aficamten, ought to let us successfully connect with the subset of cardiologists who handle roughly 80% of obstructive HCM patients. We think we hold a unique advantage for success, and we're pressing hard on all our commercial readiness preparations throughout this year. Much like our firm managed to establish an impressive R&D group that developed the strong pipeline we've covered today, we're far along in creating a commercial team that's just as exceptional, ready to work side by side with our widely admired R&D peers. United, we're breaking fresh ground for achievement, fueled by the common vision and mission we hold to assist patients. So with that, I'll hand things over to Robert Wong.

Robert Wong

executive
#6

Appreciate that, Andrew. We closed out the quarter with roughly $634.3 million in cash sitting on the balance sheet, and that gives us a two-year forward cash runway, which counts the capital we anticipate having access to through our arrangement with Royalty Pharma once the conditions are met. R&D spending for the first quarter of 2024 rose to $81.6 million, compared with $79.4 million during the same period in 2023 — mainly driven by outlays on our cardiac myosin inhibitor programs, partly offset by reduced costs for our skeletal muscle programs a year earlier. G&A costs in Q1 2024 came to $45.5 million, a decline from $49.7 million in the first quarter of 2023, largely because pre-commercial spending ran higher in the earlier year; so with that, I'll turn things back to Robert Blum.

Robert I. Blum

executive
#7

Thanks, Robert. As you've been hearing, our cohesive biology — with cardiac myosin inhibition at its core — keeps fueling shareholder value and growth as we carry out our strategy to move up to the next tier of biopharmaceutical companies. Looking at the nearer term, our attention stays on fleshing out the favorable SEQUOIA-HCM data through presentations and publications, plus getting ready for a successful aficamten launch, should it be approved, in 2025, while we keep investing in broadening our promising pipeline in line with our plans to build a specialty cardiovascular franchise. Through 2024, we've concentrated on parallel chances to sustain and grow the company by diversifying access to capital and reinforcing our balance sheet; we're ready to carry out a set of mostly non-dilutive transactions, like those that come with partnering and structured financial engineering; we hope to share more about these initiatives as they get finalized and are committed to ensuring not just diversified sources of capital, but also that we concentrate on capital efficiencies as we put capital to work advancing our pipeline and emerging commercial business. Our top priority stays our ongoing business development effort for aficamten in Japan. Over the quarter, we kept talking with multiple parties, and with momentum, we hope to get a deal done. We're also examining restructuring and expanding existing financial instruments and deals to bring down our overall cost of capital and potentially monetize further R&D progress. We expect to stay diligent regarding the various levers we can pull, as could enable us in a mainly non-equity dilutive way, to keep enhancing shareholder value, and we may also weigh equity financing at the right moment as part of a wider capital access strategy. Shaping how we conduct business now and going forward is our commitment to corporate responsibility. Not long ago, we were proud to put out our second annual corporate responsibility report, which showcases our actions and progress toward our goals of keeping patients at the heart of what we do, fostering a high-integrity, diverse, and inclusive culture, and backing sustainable communities. As we consider our longer-term goals and vision, which will be laid out in our Vision 2030 early next year, the company we want to become is a sustainable commercial enterprise with a lasting R&D organization. Our vision is to preserve our pioneering leadership in muscle biology and pharmacology, rooted in financial stewardship and doing what's right for the patients we serve. Now, I'll go over our upcoming milestones; for aficamten, we expect to present the primary results from SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress next week. We expect to submit an NDA to the FDA in Q3 2024 and an MAA to the EMA in Q4 2024. We expect to finish enrollment in MAPLE-HCM in Q3 2024 and keep enrolling in ACACIA-HCM throughout 2024. Looking ahead, CEDAR-HCM enrollment should carry on through 2024, and in Q2 2024 we anticipate kicking off a phase I trial of aficamten involving healthy volunteers in Japan. We also plan to keep pushing forward with our go-to-market efforts for aficamten. Turning to CK-586, our expectation is to share primary data from the phase I study at a medical meeting during the second half of this year, and to launch a phase II clinical trial in Q4 2024. On the preclinical development and ongoing research side, we anticipate beginning clinical development later this year with an additional muscle-directed compound, while also continuing our research and expanded muscle biology work. Operator, at this point we're ready to take questions, please. Hello, Charles.

Executive

executive
#8

Apologies. Hey everyone, Asiya here, filling in for Charles. Thanks for letting us ask something, and congratulations on everything you accomplished during the quarter; we've got a single question regarding CK-586. Given the phase I data that came out this morning, what dose will you begin with, and what escalation approach will the phase II clinical study use? Also, in what way do you intend to track safety and efficacy throughout that study? Since we haven't yet announced what the phase II study will look like, it's somewhat early to ask, but perhaps Fady and Stuart could describe in broad strokes how you think about raising the dose and what kinds of assessments you may be weighing for the phase II study.

Robert I. Blum

executive
#9

Okay, so what I'd say is this — every single dose mentioned in the press release was well tolerated. A maximally tolerated dose was never identified. Pushing things that far up wasn't necessary. A clear pharmacodynamic response showed up, and because of that, we were able to figure out how to move ahead into phase 2. On the subject of particular doses and such, I think additional comments will come from us, but what you should anticipate is that phase 2 will truly function as a dose-finding trial in patients who have heart failure with preserved ejection fraction — people who will look like those we plan to enroll in phase 3. As for monitoring right now, plus the dosing schedule and the way we're handling all of it, I'll likely keep quiet about that until the point when we're prepared to share those details more openly. Here's what you can count on: we are taking learnings related to aficamten in nHCM and applying them to CK-586 in HFpEF; our belief is that there are similarities when it comes to patient populations, and also in endpoints for clinical evidence of effect. Later in the year, we'll say more on that.

Executive

executive
#10

Okay. Thank you so much.

Robert I. Blum

executive
#11

Thank you. Hello, Paul.

Paul Choi

analyst
#12

Hey Robert. Good afternoon, and it's great to see Sung here once more and to keep collaborating with him. I'd like to ask about MAPLE, specifically regarding what you said on timing. Given that the trial is expected to have patients enrolled by Q3 of this year, you'd presumably get a look at a data cut, say, as late as the middle of next year. So what I want to know is whether you intend to submit any interim or partial data cut, or perhaps even the complete dataset, as either a safety or efficacy set, when considering your—as part of your NDA submission, whether to strengthen your argument for the proposed REMS and/or label? If you could address that, it would be wonderful. Thank you.

Robert I. Blum

executive
#13

That's a good question. I'll have Fady weigh in.

Fady I. Malik

executive
#14

Right, so the study is going to stay blinded until it reads out in 2025. That being said, within an NDA review, a 120-day safety update exists; and so we are going to submit pooled safety information from trials that are ongoing, such as MAPLE and ACACIA, plus refreshed safety, and FC data out of FOREST-HCM; therefore additional data will be there, so to speak, to take into account, and to solidify whether the safety profile of aficamten, while the NDA review is underway.

Paul Choi

analyst
#15

Okay, great. Thank you.

Robert I. Blum

executive
#16

Thank you, Paul.

Robert I. Blum

executive
#17

Good afternoon.

Srikripa Devarakonda

analyst
#18

Hey there, everyone. Thanks a lot. Good afternoon, Robert. I really appreciate you fielding my question. So, mavacamten remains at an early point in its launch, and perhaps I'm getting ahead of myself, since we need to hold off until aficamten secures approval. Still, looking somewhat further out, should it be approved, aficamten would have a sizable share of the market still open to reach. I was curious, though, about how likely it is that patients might move over from mavacamten to aficamten, whether because of worries about safety or because they aren't happy with how well it works. That might not be what you're assuming as the base case, but I just wanted to ask whether that could happen.

Robert I. Blum

executive
#19

That's a fascinating point. I believe analysts have been surveying key opinion leaders on exactly this topic, and we'll let the equity research community draw whatever conclusions it wants from those surveys. Still, our main approach is clearly to grow the category for aficamten, since it may apply to a wider range of patients and to the physicians who treat them, rather than concentrating on patients switching; though perhaps I should turn it over to Andrew to share his thoughts on the category's broader growth and penetration.

Andrew Callos

executive
#20

Right, Robert, just to add a bit to what you laid out. What I'd say is that we anticipate that most of the market — the addressable market — will remain open to us, and the real work is simply teaching physicians and the wider cardiology community about aficamten, so that they're able to guide and reach a well-informed choice regarding how a patient gets treated. We won't be out there talking about or promoting switching in any way. Should that occur, it would come about via the dialogue between the physician and the patient.

Robert I. Blum

executive
#21

You see, we've been working to learn from how other cardiovascular brands have launched and from strategies for next-in-class products, and how those approaches end up benefiting both patients and shareholders. I believe it falls to us to concentrate on the areas where cardiac myosin inhibition continues to have use for a wider range of patients, so that in the end we can deliver on our science and our mission.

Srikripa Devarakonda

analyst
#22

Understood. Thanks a lot.

Robert I. Blum

executive
#23

Respondent (Robert I. Blum): Thanks.

Robert I. Blum

executive
#24

Good afternoon.

Tessa Romero

analyst
#25

Good afternoon, and hey, Robert, plus everyone on the team. We really appreciate you taking the question. So we noticed there's a meeting coming up with the FDA during this quarter. I'm curious what your current thinking is regarding what you'll share with all of us about how that meeting turns out, particularly your discussions concerning a risk mitigation plan? Also, would there be any disclosure ahead of kicking off the NDA submission, or would there not be one, and what might that disclosure look like? Then my second question, quickly, concerns epidemiology for HCM. We were at ACC, and a major takeaway for us involved the emphasis on better diagnosis. Where do you stand right now on the correct figure, the number of patients who could be addressable when launch happens? And how much does that figure grow if the pediatric population is included? Thanks.

Robert I. Blum

executive
#26

Sure. I'll take the first one. Perhaps Fady will chime in on that, and then we'll have Andrew address numbers two and three. Regarding our approach, we don't plan to offer feedback on a play-by-play basis when it comes to regulatory interactions, particularly where REMS is concerned. We do anticipate that following the meeting with FDA, we'll have clarity about what we may elect to do regarding the possible REMS, and we'll provide a general update during our next earnings call, but not beyond that once the meeting has occurred. We feel transparency is served by at least giving some general updates, though not so detailed that it could impact the actual review and the discussions we're having with the FDA. As you're aware, ultimately it won't be until maybe a mid-cycle review that the FDA lets us know what they're thinking, and that is ultimately the most actionable thing. At that point, if this drug is hopefully approvable, we'll be negotiating around a potential REMS or other risk mitigation strategies. I don't believe it serves anyone's interest to foreshadow that before we've even submitted the NDA. Fady, is there anything you'd like to add?

Fady I. Malik

executive
#27

Sure, I’ll just add that, in my view, these kinds of talks are generally more about giving a sense of direction. They aren’t commitments in any way. What they do is help the FDA become more acquainted with the data as we understand it. Of course, they’ll still have to conduct their own assessment, so making any disclosures probably wouldn’t be all that helpful, since matters will shift during a review, and I don’t believe we’d want to create confusion for people about which way things are heading.

Robert I. Blum

executive
#28

Just to be clear, though, we do anticipate laying out various scenarios and various risk mitigation strategies, as might appear in a possible REMS. Only after that meeting will we decide how to handle that when submitting an NDA in Q3. With that, perhaps I'll hand things over to Andrew for questions two and three.

Andrew Callos

executive
#29

Okay, regarding diagnosis, I'll focus only on obstructive HCM. Currently, there are 200,000 patients who have been diagnosed, and among them, 130,000 would qualify for therapy based on New York Heart Association Class II or III criteria. As with many rare conditions, that figure probably underrepresents the actual prevalence, since a lot of people go undiagnosed, yet the real prevalence is likely three or four times larger. Also, it's fairly common that when a treatment becomes available on the market, guidelines get revised so that treatment is included. There's education and publications from pharmaceutical companies. Those rates will begin rising, and that's what we anticipate happening. When it comes to the pediatric group, out of the 200,000 obstructive HCM patients diagnosed in the US and Europe—which are comparable—there are roughly 6,000 to 8,000 pediatric patients with HCM. So, I'm assuming—well, we don't actually have a New York Heart Association class breakdown for pediatric patients—but assuming around 50%-60% of that group would be eligible for treatment; so hopefully that addresses your question.

Tessa Romero

analyst
#30

Thank you.

Robert I. Blum

executive
#31

Thank you.

Robert I. Blum

executive
#32

Good afternoon.

Roanna Ruiz

analyst
#33

Afternoon. Hi, everyone. So I'd like to ask a follow-up question regarding the CEDAR-HCM trial that involves pediatric patients. Could you discuss a little the unmet need that exists there for a therapy such as aficamten within this specific segment of the HCM market? Also, how long could it potentially take before that trial is actually finished, and do you have any opinions about the regulatory path forward, assuming you obtain positive data from CEDAR?

Fady I. Malik

executive
#34

Yeah, so, you know, I think the pediatric population's not as large as the adult population, but there's a significant unmet need. You heard Andrew comment on it, on the size. They have the same types of treatment options available to them that adults do, but surgery is a much less preferred option in that age group, if you will. The availability of a myosin inhibitor, I think, would be quite meaningful as an option for these patients who, when they manifest disease at, you know, an early age like this, it can be quite aggressive. So we may also over time be able to generate information that looks at how potentially the disease is stabilized as opposed to progressive. And in this subgroup, that may be more amenable because their disease may progress more rapidly. I think when you talk about any pediatric patient population, you know, the FDA in general is very accommodating to trying to move those things as quickly as possible through the review process. We would expect these data to be positive, just given the you know, the main endpoint is reduction of the left ventricular outflow tract gradient. And so once we have these trials done, we're not really guiding it to how long it'll take, but we think it'll go fairly quickly. We can file this as part of a supplemental NDA.

Roanna Ruiz

analyst
#35

Got it. Thanks.

Fady I. Malik

executive
#36

Thank you, Aurora.

Fady I. Malik

executive
#37

Hi, Salim.

Salim Syed

analyst
#38

Hi, Robert. Good afternoon, everyone; I'd also like to say welcome and congratulations to Sung. It's great to talk with you again, Sung. I suppose regarding CK-586, if I may — I realize you might not be giving specific information about the phase II design, and maybe this question is for Fady. But Fady, is there anything specific from the phase I trial that you discovered about how this compound might potentially stand apart from the MyoKardia 224 compound, and what that read across means for how a trial could differ from their current phase II study?

Fady I. Malik

executive
#39

That's a tough question to address, Salim, since we don't actually know a great deal about 224, and we haven't shared much with you about 586. You know, I suppose I'll simply say — and then perhaps we can have Stewart add a bit — that our aim is to make dosing of 586 easier than aficamten, and we believe it possesses some distinctive properties that could allow for that, as we observed in phase I. Stewart, would you like to perhaps say a little more?

Stuart Kupfer

executive
#40

The one point I'd genuinely tack on is this: CK-586 came out of a design process aimed at a group we see as more vulnerable. That means patients dealing with HFpEF — and HFpEF comes with a lot of comorbidities, so these folks may run a greater chance of things like a drop in ejection fraction. Our view is that CK-586 carries attributes that ought to keep such patients easier to handle and less likely to hit that problem or other dangers. So once more, more specifics on all of that will come out soon.

Salim Syed

analyst
#41

Alright, I understand. Thanks a lot.

Fady I. Malik

executive
#42

Thanks.

Stuart Kupfer

executive
#43

Thank you.

Robert I. Blum

executive
#44

Hi, Jeff.

Jeff Hung

analyst
#45

Hello, Robert, and hello to everyone else on the call. I appreciate you letting me ask something, and Sung, congratulations on stepping into your new position. Regarding CEDAR, what dose range do you anticipate will probably be enough for the majority of pediatric and adolescent patients? Should those doses turn out to be comparable to what patients received in SEQUOIA, do you think there would be a greater incidence of ejection fraction excursions given the age-related differences? Thank you.

Fady I. Malik

executive
#46

Stuart, would you like to handle that question?

Stuart Kupfer

executive
#47

Hello Jeff, and thank you for raising that. As you pointed out, adolescent patients receive doses identical to those under investigation for adults — ranging from 5 to 20 milligrams. And once again, the crucial point is that dose selection gets tailored for each individual, guided by whether the target gradient is achieved and a normal ejection fraction is maintained. When it comes to younger children, the central issue really becomes: what constitutes a safe starting dose? Our approach will be, as I noted earlier, to conduct an interim analysis, assess 20 adolescent patients for pharmacokinetics and safety, and then establish what a safe starting dose looks like for the younger children. That essentially captures the strategy. So with individualized dose selection in mind, we expect the benefit-risk ratio for children to be every bit as favorable as what we are seeing in adults.

Jeff Hung

analyst
#48

Great. Thank you.

Stuart Kupfer

executive
#49

Thank you.

Mayank Mamtani

analyst
#50

Hello, everyone. We appreciate you answering our questions, and it's also nice to see Sung joining the group. Perhaps regarding the data coming at next Monday's ESC Heart Failure Congress, might you clarify whether we could receive the patient-level safety analysis compared with what we observed in the top line? Also, naturally, we're interested to learn how much the dose titration and the responder rate among patients remaining at higher efficacious doses contributes to that peak VO2 figure, which appears to be on the higher side and isn't tied to the baseline characteristics we originally assumed. If you could shed light on that, it would be excellent.

Fady I. Malik

executive
#51

Yes. Hi, Mayank. I think the bulk of your questions are going to be covered in those presentations. Keep in mind, there are three of them. One will discuss dosing and safety extensively, so we'll show the traits of patients across the different doses and how safety tied into that. Regarding peak VO2, I can't really say. I'm not aware of any dose-specific analysis, but bear in mind, these patients weren't randomized to dose. Randomization was to a dosing strategy, and they reached a dose according to their own response to the drug. So in that sense, we largely view them all as belonging to the same dosing strategy.

Mayank Mamtani

analyst
#52

Understood. I appreciate you letting me ask. Answer from Fady I.

Fady I. Malik

executive
#53

Malik: Happy to help.

Jason Butler

analyst
#54

Hello, and thank you for fielding this. Congratulations on everything that has been accomplished so far. Could you share where things stand with regulators in China, and what comes next? Appreciate it.

Robert I. Blum

executive
#55

Hi, Jason. That's one I can address. Given the circumstances, things are moving along quite well. However, we can't provide specifics at this point, not until we and our partner Ji Xing have reached agreement on how to frame those expectations. My hope is that we can share more by the time of the following earnings call.

Jason Butler

analyst
#56

Okay, great. Thank you.

Robert I. Blum

executive
#57

Hello, Jason.

Cameron Bozdog

analyst
#58

Hi there, good afternoon. Cameron Bozdog here, filling in for Jason. You brought up the possibility of a new kind of REMS built around a risk algorithm. Could you expand a bit on what that might actually involve? Also, has any input come back from the regulators regarding this? And then, if possible, could you speak to your current base case expectations for how many echoes will probably be needed, both during titration and in the maintenance phase? Thanks.

Robert I. Blum

executive
#59

Sure. Addressing the second half of what you asked would be premature right now. How many echoes are needed depends on discussions that are still ahead of us with FDA. That said, I don't see any situation where we'd anticipate a REMS resembling the existing one. Given that the dosing approach used in SEQUOIA-HCM and carried forward in FOREST-HCM is itself distinctive, and that connects directly to how risk gets mitigated, it should be evident that a REMS program of a different type will be in place. Beyond that, we look forward to engaging with FDA on what that might concretely look like, guided by whatever direction we take on risk mitigation when we file an NDA. As you're aware, there are multiple routes for handling risk mitigation. Certain elements can be addressed through labeling. Certain elements can be addressed via an informational REMS. Certain elements might call for an ETASU REMS, and the cardiac myosin inhibitor currently on the market operates under an ETASU REMS. What we aim to do is grasp how FDA views risk, not only regarding the EF excursions that seem to draw Wall Street's attention, but also when it comes to ADME properties, drug-drug interaction properties, and pharmacokinetic properties relating to half-life and the shape of the pharmacodynamic curve. Each of these considerations plays into how risk mitigation gets designed, and I genuinely believe we'll be positioned — this is our base case — to offer a differentiated risk mitigation profile. That's really all I can offer at this point, though we're hopeful there will be more to share later on.

Cameron Bozdog

analyst
#60

Got it. Thank you.

Robert I. Blum

executive
#61

Thank you.

Fady I. Malik

executive
#62

Hello there, Carter.

Carter Gould

analyst
#63

Okay, good af- hi, Robert, everyone, good afternoon. I appreciate you fielding this. What I'm about to pose is somewhat of an unfair query, since the AHA and ACC HCM guideline was released only this afternoon; even so, I'll take a chance and suggest you likely already had a solid idea regarding its contents; so, broadly speaking, does anything within it catch you off guard? And, perhaps—though this may stir things up for Diane and the operator—considering, for... I suppose for Andrew, when you reflect on how much these guidelines will matter later on, communicating that distinction between mavacamten and aficamten, how significant is that, given all the earlier case study efforts you've completed? Thank you.

Robert I. Blum

executive
#64

Yes, so, credit to you for pointing out that those guidelines came out just today. I'll have Fady and Andrew each weigh in from where they sit, given what you asked, and incidentally, you did make Diane smile.

Fady I. Malik

executive
#65

Okay, so two hours prior to this call, the guidelines showed up in my inbox, and honestly, I didn't notice them until we were already partway through this call. So I'll try my best to address your question, and having given them a quick look, I'd say first off, they concern a category of myosin inhibitors, and… nothing particularly unexpected, in my view. They took more or less the same tack as the EMA and the ESC guidelines, essentially positioning cardiac myosin inhibitors after first-line treatment with beta blockers, or for patients who don't respond to first-line therapy, something like that. That's the reason we're running MAPLE, potentially, to demonstrate there are benefits from using cardiac myosin inhibitors as the initial treatment, and hopefully those results will shape later guidelines. There are certain particular points where they blur things regarding cardiac myosin inhibitors that are in fact specific to a compound rather than to cardiac myosin inhibitors as a whole. I won't spell those out, but I believe if you go through them, you'll work that out. So a few of those may, down the road, need to be clarified. And we'll simply have to try our hardest to make certain that such information reaches the individuals responsible for the guidelines. We definitely had no knowledge of what the guidelines contained; we don't take part in that process, you know, but we can ensure the data gets to them. And I anticipate-

Andrew Callos

executive
#66

And Kurt — oh, my mistake, Scotty.

Fady I. Malik

executive
#67

Andrew, please continue.

Andrew Callos

executive
#68

Yeah, the one thing I might have tacked onto what you asked about concerns the guidelines. Obviously, when you're speaking with physicians about evidence, it brings credibility; and it definitely brings credibility with payers when it comes to covering something, particularly if that's a first-line therapy. More studies also lend additional strength to a guideline. And what's probably hugely important is if a guideline, for instance, discusses, let's say, first-line therapy on the basis of data such as MAPLE, then having those data and that evidence and being in a position to discuss it with physicians, versus lacking that evidence and being unable to discuss it with physicians, I believe that's a major distinction; so, you know, so I think the guideline is helpful, you know, to perhaps sum up, in terms of credibility with different stakeholders, and, probably most crucially, it allows us, as a pharmaceutical company, to speak with physicians and payers about the evidence regarding aficamten should we receive approval. Thank you.

Yasmeen Rahimi

analyst
#69

Thanks, everyone, for sharing all that useful information. So, with the Cardiology Heart Failure Congress starting this Monday, I suppose you've mentioned that the deeper one digs into the data, the stronger it looks. Do you believe — and this is, I think, what folks are wondering ahead of Monday's release of the data, or the complete disclosures surrounding it — that it will turn out even more obvious that aficamten comes out ahead regarding efficacy, and not merely when it comes to the safety aspect of its profile? I'd really like to hear your perspective on that, and then I'll rejoin the line at the end.

Robert I. Blum

executive
#70

Let me be clear: a head-to-head trial pitting aficamten against mavacamten was never run by us, and suggesting otherwise would be improper. That being said, we feel that aficamten's profile in Sequoia — covering efficacy, safety, convenience, and every element that plays into its next-in-class standing — is going to be backed up by the evidence, which would reflect our conviction that, if approved, aficamten could eventually turn into the preferred cardiac myosin inhibitor; nonetheless, once you've reviewed the data, that decision rests with you in the end. These results are going to be made available not only through presentations, but through publications as well, and not solely at the European Heart Failure Meeting, but at additional meetings across the remainder of this year. And I genuinely think these results confirm what we've been expecting.

Yasmeen Rahimi

analyst
#71

Thanks a lot. Can't wait for Monday.

Robert I. Blum

executive
#72

Thanks.

Amy Li

analyst
#73

Hi, this is Amy, filling in for Akash. We really appreciate you answering our question. I just have one about CK-586. In your view, will this drug require LVEF monitoring? Also, what does your healthy volunteer data show that either backs up or argues against that requirement? Thank you very much.

Fady I. Malik

executive
#74

I suppose I can address that. As I see it, we created CK-586 as a possible way to give it to HFpEF patients without echo monitoring — without routine echo monitoring. Having said that, we still must generate the evidence that ultimately backs that up, and I believe it's too early to say with certainty whether we'll get there. What we observed in phase one moved us in that direction. So we'll learn more as we continue studying this drug in phase two.

Ashwani Verma

analyst
#75

Understood. Many thanks.

Robert I. Blum

executive
#76

Hi there, Serge. Good afternoon to you.

Serge Belanger

analyst
#77

Hello, and good afternoon, Robert. Thus far you've held 2 meetings with the FDA, with, I believe, another scheduled sometime later in this quarter. At this point, how do you view the chances of a priority review or an Ad com? Thank you.

Robert I. Blum

executive
#78

Right. Well, our base case assumptions include neither of those. Given a next-in-class profile, assuming priority review would be the more extraordinary outcome; it's definitely possible, though that isn't something we're counting on, if you will. And when it comes to an AdC om, our expectation is none, but such things can catch you off guard; and given that, in our view, the data are quite compelling, there's already a very effective cardiac myosin inhibitor being sold that had no AdC om. Now having an AdC om for a next-in-class compound would strike me as unusual, but I suppose in theory it could happen. That's not what our base case assumes.

Serge Belanger

analyst
#79

Understood. Appreciate it.

Ashwani Verma

analyst
#80

Hello, and thank you for fielding our questions. Concerning the presentation that happened on Monday, from where you sit, what do you figure the threshold is for the LVEF under 40% occurrence, based on SEQUOIA? What amount of LVEF beneath 40% would leave you convinced that the FDA could genuinely be capable of distinguishing your safety profile when compared with Camzyos? Then, secondly, regarding the oHCM market, over the long term, do you believe there's substantial diagnosis expansion you could generate? Investors sometimes put oHCM alongside ATTR, and that condition has experienced quite meaningful diagnosis expansion. If you could just explain how the two differ? Thank you.

Robert I. Blum

executive
#81

So I may turn to Fady to address the remarks regarding EF below 40, though keeping in mind that our top-line press release already touches on a few of those points.

Fady I. Malik

executive
#82

Right, I was about to mention that, as we noted regarding our top line, there were no treatment discontinuations for EF below 40%. And as you know, the protocol required those if sites observed them; we'll go into more detail on that during the presentation, I imagine. But then again, I don't believe an N of zero or one will really add all that much, so to speak. It's good to be aware of things that don't occur, and they certainly back up the safety profile. We've never seen, you know, a heart failure event attributable to aficamten. And treatment interruptions have been pretty much nonexistent. So overall, I'd say all of those are quite encouraging with respect to possible labeling further down the line. I don't think we caught your second question, which I assume we'll take up.

Ashwani Verma

analyst
#83

Sure, and quickly, on the topic of expanding diagnosis for oHCM — someone might say there's a big unmet need, yet the death or illness toll isn't as large as with something like ATTR, which has experienced a major rise in diagnoses. So do you think that over time, you could really push a lot of diagnostic growth? Bristol has run many DTC and other marketing efforts, yet still isn't creating any meaningful upturn for Camzyos. So I'm just trying to figure out whether this oHCM market is basically where it will stay, or whether we might see substantial growth eventually.

Andrew Callos

executive
#84

Yeah, I don't think the burden of this disease is measured by mortality rates so much as by symptoms and other factors that affect daily function and quality of life. And it's quite evident that people who get a cardiac myosin inhibitor stick with and comply with their treatment very well. Look at the Camzyos data. These are patients gaining a great deal from a new therapy and who wish to remain on it. And I do think that will ultimately determine what the opportunity for category expansion might be. Andrew, anything to add? Yeah, I'd say that's likely part of what HEOR is tasked with. Consider some of the secondary endpoints, such as improvement in New York Heart Association, improvement in KCCQ, reduction in the need for septal therapy and surgery — all of those point to better health outcomes and greater cost savings. So I think you'll begin to see more publications and us speaking to that, and then combining that with large data sets to demonstrate the effect it can have on bigger populations. So it might not be as evident as something like TTR, but it's definitely something I think you'll observe over time — that the expertise we have in HEOR in this area will certainly lead to what you're describing.

Robert I. Blum

executive
#85

Hey there, Sean.

Sean McCutcheon

analyst
#86

Hey, everyone. Hello, Robert. I appreciate you fitting me in. Could you share your thoughts on which patients are going to be recruited into the phase two trial for 586? ... or perhaps which subsets you believe carry the most obvious pathophysiologic justification, and what's your thinking regarding, the phase 2 when it comes to breaking down the, the HFpEF subsets and, and maybe a rough sense of how big the opportunity is across those respective populations? Thanks.

Fady I. Malik

executive
#87

Yes, absolutely. I'll, I'll have Stuart field that one, though speaking in, in broad terms. I, I want to note upfront that, like Robert mentioned before, you know, the NHCM patients who did so well in the phase 2 study sort of serve as a human model, of, of the kind of HFpEF patients we would want to investigate with CK-586, and perhaps Stuart can go into more detail on those characteristics in general.

Stuart Kupfer

executive
#88

Yeah, thank you, Fady. I think you've got that right. Our belief is that within a subgroup of patients who have severe diastolic dysfunction, the condition might largely be driven by those with hypercontractility, and a number of these individuals go on to develop ventricular wall thickening, you know, much the same as what we see in non-obstructive HCM patients. And so, the results we saw among patients during phase two in REDWOOD-HCM, but with non-obstructive HCM, truly suggest, you know, a possible benefit, an improvement in diastolic function within that HFpEF subgroup. We are going to be looking at, we are going to be evaluating patients who have, you know, a fairly high ejection fraction, a certain amount of ventricular wall thickening, who are, who are symptomatic, and experiencing functional and symptomatic, you know, heart failure symptoms tied to their, to their disease, to determine whether those patients might gain from treatment. So that is broadly the population we intend to target.

Robert I. Blum

executive
#89

Andrew, could you give us a rough, big-picture sense of how we’re viewing the HFpEF subgroups when it comes to prevalence? Andrew, it seems your line is muted.

Andrew Callos

executive
#90

Right, so HF and HFpEF — as you likely noticed in our press releases — account for roughly 50% of the total market. What we're talking about here is one subset within HFpEF, sitting at the higher end when it comes to ejection fraction. My sense is that as we gain more understanding during phase two, we'll be able to narrow down more precisely how large that subset actually is and where the cutoff point falls.

Sean McCutcheon

analyst
#91

Thank you. Thank you.

Robert I. Blum

executive
#92

Operator, I appreciate it, and thanks to the analysts for those great questions. It's exciting for us to have given you this update, particularly when it comes to the broader emphasis we now have on the aficamten development program, and at the same time, we feel we're acting as solid financial stewards when we consider capital, diversification, capital deployment, and efficiencies. We look forward to bringing you news of further progress, and that includes our presentations next week — Monday, May 13 — at the European Heart Failure Meetings, and after that as well. We're grateful for the interest you've shown in Cytokinetics, and we can't wait for the next earnings call. Operator, that being said, we're ready to wrap up the call now.

Operator

operator
#93

Thanks for joining us; that brings today's conference call to a close. We appreciate everyone taking part. At this point, you're free to disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.